StreetInsider.com News Articles

Form SCHEDULE 13G Immix Biopharma, Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Fri, 14 Aug 2026 11:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26927299.html

Form SCHEDULE 13G Immix Biopharma, Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Fri, 14 Aug 2026 11:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26927299.html

Immix Biopharma (IMMX) Reiterated at Market Outperform by Citizens on Upcoming Milestones

Fri, 14 Aug 2026 04:32:48 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $23.00 price target on Immix Biopharma, Inc. (NASDAQ: IMMX).

The analyst commented, "We reiterate our Market Outperform rating and price target of $23 for Immix Biopharma based on a revenue and earnings multiples analysis. Recently, Immix reported 2Q26 earnings, and based on our conversation with management, we remain confident in regard to the cadence of value-driving milestones over the next 6-12 months. With NXC-201 on track to report top-line results in September and file a BLA in 1H27, a potential commercial launch by year-end 2026/early 2027, and a solid cash position

Form SCHEDULE 13G/A Immix Biopharma, Inc. Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26919254.html

Form SCHEDULE 13G/A Immix Biopharma, Inc. Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26919254.html

Immix Biopharma, Inc. (IMMX) PT Lowered to $19 at Morgan Stanley

Tue, 11 Aug 2026 09:09:10 -0400

Morgan Stanley analyst Judah Frommer lowered the price target on Immix Biopharma, Inc. (NASDAQ: IMMX) to $19.00 (from $20.00) while maintaining a Overweight rating.

Immix Biopharma, Inc. (IMMX) PT Raised to $25 at H.C. Wainwright

Mon, 10 Aug 2026 06:51:43 -0400

(Updated - August 10, 2026 6:51 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Immix Biopharma, Inc. (NASDAQ: IMMX) to $25.00 (from $20.00) while maintaining a Buy rating.

The analyst commented: "For 2Q26, Immix reported a net loss of $0.18 per share vs. our prior estimate of a net loss of $0.15 per share. R&D and SG&A expenses were $5.3M and $7.1M respectively, vs. our prior estimates of $6.2M and $4.9M. We now project a full-year 2026 net loss of $0.72 per share vs. our prior net loss estimate of $0.62 per share. Immix ended 2Q26 with ~$234.2M

Immix Biopharma, Inc. (IMMX) PT Raised to $25 at H.C. Wainwright

Mon, 10 Aug 2026 06:51:43 -0400

(Updated - August 10, 2026 6:51 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Immix Biopharma, Inc. (NASDAQ: IMMX) to $25.00 (from $20.00) while maintaining a Buy rating.

Form 10-Q Immix Biopharma, Inc. For: Jun 30

Fri, 07 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260807/26892086.html

Form 10-Q Immix Biopharma, Inc. For: Jun 30

Fri, 07 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260807/26892086.html

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Tue, 04 Aug 2026 09:15:00 -0400

LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference being held September 14-16, 2026 in New York, NY.

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Morgan Stanley representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Tue, 04 Aug 2026 09:15:00 -0400

IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Losses

Thu, 23 Jul 2026 08:15:00 -0400

Boston, Massachusetts--(Newsfile Corp. - July 23, 2026) - Block & Leviton is investigating Immix Biopharma (NASDAQ: IMMX) for potential securities law violations. Investors who have lost money in their Immix Biopharma investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/immx.

What is this all about?

Block & Leviton is investigating whether Immix Biopharma or certain of its executives violated federal securities laws. According to news reports, a person who had been serving as an Immix executive under the name "Richard Graydon" was in fact allegedly a Rhode Island most-wanted fugitive

IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Losses

Thu, 23 Jul 2026 08:15:00 -0400

What is this all about?

Needham Starts Immix Biopharma, Inc. (IMMX) at Buy

Wed, 22 Jul 2026 06:55:22 -0400

Needham analyst Gil Blum initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $21.00.

For an analyst ratings summary and ratings history on Immix Biopharma, Inc. click here. For more ratings news on Immix Biopharma, Inc. click here.

Shares of Immix Biopharma, Inc. closed at $9.57 yesterday.

Immix Biopharma shares fall 13% after executive arrested as fugitive

Mon, 20 Jul 2026 12:15:07 -0400

Shares of Immix Biopharma, Inc. (NASDAQ: IMMX) fell more than 13% during intraday trading on July 20, 2026, after a report revealed that a company executive had been arrested as a long-sought fugitive.

According to a report by STAT News, Ronald Fischer, 70, a former anesthesiologist who disappeared in 2005 while on trial for first-degree sexual assault, had been working as an executive at Immix Biopharma. Federal and Rhode Island authorities arrested Fischer after tracking and boarding a 56-foot sailboat off the coast of New Jersey.

Kehoe Law Firm, P.C., a Philadelphia-based plaintiff-side law firm, stated it is investigating potential securities fraud

Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims

Mon, 20 Jul 2026 12:13:00 -0400

Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma") (NASDAQ: IMMX).

On July 20, 2026, Investing.com reported that "Immix Biopharma Inc . . . shares fell 13% . . . after STAT News reported that one of Rhode Island's most-wanted fugitives appears to have been working as an executive at the company."

Additionally, "[a]ccording to the report, Ronald Fischer, 70, was arrested last week by federal and Rhode Island authorities after they tracked and boarded a 56-foot sailboat off

Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims

Mon, 20 Jul 2026 12:13:00 -0400

Additionally, "[a]ccording to the report, Ronald Fischer, 70, was arrested last week by federal and Rhode Island authorities after they tracked and boarded a 56-foot sailboat off

Form 8-K Immix Biopharma, Inc. For: Jul 20

Mon, 20 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260720/26786553.html

Form 8-K Immix Biopharma, Inc. For: Jul 20

Mon, 20 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260720/26786553.html

BofA Securities Starts Immix Biopharma, Inc. (IMMX) at Buy

Thu, 18 Jun 2026 06:11:26 -0400

(Updated - June 18, 2026 6:11 AM EDT)

BofA Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $27.00.

The analyst comments "We initiate coverage of IMMX with a Buy rating and $27 PO. IMMX is developing NXC201 for AL amyloidosis, a rare disease with damaged vital organs and no approved treatments. Early data of NXC-201 shows ~95% complete response and rapid minimal residual disease in relapsed/refractory (r/r) AL amyloidosis. The safety profile was favorable for patients facing potential organ failure with no observed neurotoxicity. Updated phase 2 data is

BofA Securities Starts Immix Biopharma, Inc. (IMMX) at Buy

Thu, 18 Jun 2026 06:11:26 -0400

(Updated - June 18, 2026 6:11 AM EDT)

BofA Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $27.00.

BofA Securities Starts Immix Biopharma, Inc. (IMMX) at Buy

Thu, 18 Jun 2026 06:11:26 -0400

(Updated - June 18, 2026 6:11 AM EDT)

BofA Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $27.00.

BofA Securities Starts Immix Biopharma, Inc. (IMMX) at Buy

Thu, 18 Jun 2026 06:11:26 -0400

(Updated - June 18, 2026 6:11 AM EDT)

BofA Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $27.00.

Form SCHEDULE 13G/A Immix Biopharma, Inc. Filed by: JANUS HENDERSON GROUP PLC

Fri, 05 Jun 2026 12:57:00 -0400

si-local-file:///var/storage/secattach/20260605/26610062.html